Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Sunshine Biopharma (SBFM) over the last 9 years, with Q3 2025 value amounting to $649850.0.

  • Sunshine Biopharma's Change in Receivables rose 16584.19% to $649850.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 3463.56%. This contributed to the annual value of $2.3 million for FY2024, which is 29354.21% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Change in Receivables of $649850.0 as of Q3 2025, which was up 16584.19% from -$65711.0 recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Change in Receivables peaked at $1.8 million during Q2 2024, and registered a low of -$986986.0 during Q3 2024.
  • Its 5-year average for Change in Receivables is $212951.2, with a median of $6669.0 in 2021.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 316620000.0% in 2023, then tumbled by 165867.79% in 2024.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Change in Receivables stood at $6669.0 in 2021, then surged by 7881.14% to $532262.0 in 2022, then decreased by 10.63% to $475659.0 in 2023, then soared by 113.81% to $1.0 million in 2024, then plummeted by 36.1% to $649850.0 in 2025.
  • Its Change in Receivables was $649850.0 in Q3 2025, compared to -$65711.0 in Q2 2025 and -$426673.0 in Q1 2025.